

Pharmacy BULLETIN BOARD

Industry Issue ■ Monday June 9, 2014

UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
UriSec® 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec® 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
UriSec® 22% Cream NPN 00396125	120 g	220Q	46312	115444	26623201
	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
UriSec® 40 Cream NPN 80005531	15 g	45014	114939	003743	-
	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com



UriSec® is a registered trademark of Odan Laboratories Ltd.

STERIMAX INC.

VANCOMYCIN HYDROCHLORIDE FOR INJECTION
500mg, 1g, and 10g AVAILABLE!

SteriMax Inc. is pleased to announce the availability of **Vancomycin Hydrochloride for Injection 500mg, 1g, and 10g.**

To order, **Vancomycin Hydrochloride for Injection** please contact the appropriate wholesaler listed below or SteriMax Inc. customer service at 1-800-881-3550.

SteriMax Code	DIN	UPC	Strength	Format	Pack Size	McKesson	K+F
ST-BK212	02411032	834324000275	500 mg	Vial	10	063153	n/a
ST-BK112	02396386	834324100906	1 g	Vial	10	057723	n/a
ST-BK311	02411040	834324000312	10 g	Vial	1	052854	145724

 **Maximizing the Wellness of Canadians**

www.sterimaxinc.com



New Product from Taro!!!

P^rTaro-Carbamazepine

Carbamazepine Tablets

Taro Pharmaceuticals is pleased to announce the launch of Taro-Carbamazepine Tablets 200mg

- Bioequivalent to Tegretol^{®1}
- High Quality, Lower Price Alternative
- Anticonvulsant; Symptomatic Relief of Trigeminal Neuralgia; Antimanic²
- Available for Immediate Shipping

Form	Strength	DIN	Size	UPC
Tablets	200 mg	02407515	500	063691072671

For more information, or to place an order for Taro-Carbamazepine 200 mg Tablets, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.

² P^rTaro-Carbamazepine Product Monograph.

[®] Tegretol is a registered trademark of Novartis Pharmaceuticals Canada Inc. TARO is a registered trademark of Taro Pharmaceuticals Inc.



Recently Launched Product from Taro!!!

P^rTaro-Diclofenac

Diclofenac Sodium Topical Solution 1.5%

Taro Pharmaceuticals is pleased to announce the recent launch of Taro-Diclofenac Topical Solution 1.5% which is Available for Immediate Shipping.

- Bioequivalent to Pennsaid^{®1}
- High Quality, Lower Price Alternative
- Topical Anti-inflammatory; Analgesic²
- New Convenient 150 mL Size

Form	Strength	DIN	Size	UPC	Wholesaler			
					McKesson	K&F	Procurity	McMahon
Topical Solution	1.5%	02420988	2 x 60 mL	063691073517	060770	147411	256323	10071421
			150 mL	063691073548	060771	147409	256480	10071400

For more information, or to place an order for Taro-Diclofenac topical solution 1.5%, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975** or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.

² P^rTaro-Diclofenac Product Monograph.

[®] Pennsaid is a registered trademark of Nuvo Research Inc. TARO is a registered trademark of Taro Pharmaceuticals Inc.

■ FROM THE NEWSWIRE ■



**A Lower Cost Generic Alternative of
Imitrex® Injection¹**

P^rTaro-Sumatriptan

Sumatriptan Succinate Injection 6mg/ 0.5mL

- Generic Version of Imitrex® Injection¹
- High Quality, Lower Price Alternative
- One piece device with no assembly required
- Indicated for the Relief of Migraine Headache²

Form	Strength	DIN	Size	UPC	Wholesaler			
					Mckesson	K&F	Procurity	McMahon
Subcutaneous Injection	6 mg / 0.5 mL	02361698	2 x 0.5 mL	063691068056				
					010333	119700	251763	10056869

For further information, or to place an order for Taro-Sumatriptan Injection, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at www.taro.ca.

¹Data on file, Taro Pharmaceuticals Inc.
²Taro-Sumatriptan Product Monograph
[®]Imitrex is a registered trademark, used under license of GlaxoSmithKline Inc.
 Taro is a registered trademark of Taro Pharmaceuticals Inc.

MISSISSAUGA, ON: Novo Nordisk has announced that the Québec government has approved the inclusion of Victoza® (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue, to the Lists of Medications, effective June 2, 2014. The reimbursement of Victoza® by the Québec Health Insurance Board (RAMQ) will allow people living with type 2 diabetes to have access to a treatment to help better manage diabetes. Québec is the first province to provide public access to Victoza®.

MONTREAL: A Canadian study has identified a new strategy for improving the care of patients living with Type 2 Diabetes (T2D) by empowering them to manage their own insulin therapy. The START study (Self-Titration with Apidra® to Reach Target)¹, the first research of its kind, found that T2D patients adjusting their own insulin doses can control the disease and achieve blood sugar targets just as safely and effectively as patients whose treatment is being conventionally managed by their physicians.

NEW YORK, USA and LAVAL, CANADA: Aven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. a drug development company focused on rare diseases, has announced that the KIACTA™ Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients. Eligible patients currently in screening will also be given the opportunity to enroll in the study likely increasing total recruitment beyond 230 patients.

To include your communication in the next issue, please contact: Health Response

T: 416-863-5403 | F: 416-863-9620 | hrc@healthresponse.ca

Next Issue: Monday June 23rd, 2014

Deadline: Thursday June 19th, 2014